Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -17.83% is 38% above its 5-year average of -28.95%, near the high end of its 5-year range (-74.25%–-4.41%).
As of the fiscal period ended Tuesday, June 30, 2026. 20.54% below its 12-month average of -14.79%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -17.83%.
RETURN ON EQUITY (ROE)
-17.83%
RETURN ON EQUITY (ROE) AVG TTM
-14.79%
RETURN ON EQUITY (ROE) AVG 3Y
-19.00%
RETURN ON EQUITY (ROE) AVG 5Y
-28.95%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-20.54%
CURRENT VS 3Y AVG
+6.17%
CURRENT VS 5Y AVG
+38.41%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+57.56%
vs the sector median at left
RxSight, Inc.
Market Cap
$192.89M
Return on Equity (ROE)
-17.83%
TTM Avg
-14.79%
3Y Avg
-19.00%
5Y Avg
-28.95%
Market Cap
$190.42M
Return on Equity (ROE)
-121.76%
TTM Avg
-56.28%
3Y Avg
-58.50%
5Y Avg
-52.63%
Market Cap
$195.80M
Return on Equity (ROE)
N/A
TTM Avg
213.11%
3Y Avg
66.34%
5Y Avg
24.75%
Market Cap
$189.11M
Return on Equity (ROE)
-136.83%
TTM Avg
-43.45%
3Y Avg
-452.04%
5Y Avg
-306.86%
Market Cap
$198.84M
Return on Equity (ROE)
-154.90%
TTM Avg
-136.39%
3Y Avg
-122.19%
5Y Avg
-93.38%
Market Cap
$199.21M
Return on Equity (ROE)
N/A
TTM Avg
620.74%
3Y Avg
332.27%
5Y Avg
266.26%
Market Cap
$200.96M
Return on Equity (ROE)
N/A
TTM Avg
-280.12%
3Y Avg
-179.90%
5Y Avg
-133.80%
Market Cap
$182.60M
Return on Equity (ROE)
-47.78%
TTM Avg
-64.50%
3Y Avg
-55.96%
5Y Avg
-125.52%
Market Cap
$179.75M
Return on Equity (ROE)
-44.23%
TTM Avg
-36.61%
3Y Avg
-30.86%
5Y Avg
-42.66%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| RxSight, Inc. (RXST) | $192.89M | -17.83% | -14.79% | -19.00% | -28.95% |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $190.42M | -121.76% | -56.28% | -58.50% | -52.63% |
| Surrozen, Inc. (SRZN)vs › | $195.80M | N/A | 213.11% | 66.34% | 24.75% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | -136.83% | -43.45% | -452.04% | -306.86% |
| Exagen Inc. (XGN)vs › | $198.84M | -154.90% | -136.39% | -122.19% | -93.38% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $199.21M | N/A | 620.74% | 332.27% | 266.26% |
| Alector, Inc. (ALEC)vs › | $200.96M | N/A | -280.12% | -179.90% | -133.80% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $182.60M | -47.78% | -64.50% | -55.96% | -125.52% |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.75M | -44.23% | -36.61% | -30.86% | -42.66% |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.47M | -21.57% | -470.91% | -299.18% | -180.76% |
ROE
-17.8%
ROA
-13.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -17.83% |
| 2026-03-31 | -17.45% |
| 2025-12-31 | -14.13% |
| 2025-09-30 | -12.95% |
| 2025-06-30 | -11.60% |
| 2025-03-31 | -9.50% |
| 2024-12-31 | -9.76% |
| 2024-09-30 | -11.07% |
| 2024-06-30 | -13.36% |
| 2024-03-31 | -27.14% |
| 2023-12-31 | -30.31% |
| 2023-09-30 | -34.09% |
| 2023-06-30 | -37.82% |
| 2023-03-31 | -43.01% |
| 2022-12-31 | -74.25% |
| 2022-09-30 | -69.70% |
| 2022-06-30 | -57.04% |
| 2022-03-31 | -48.29% |
| 2021-12-31 | -35.22% |
| 2021-09-30 | -4.41% |
